Clinical Trials Directory

Trials / Completed

CompletedNCT04176367

An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants

AN OPEN LABEL, RANDOMIZED, SINGLE DOSE, 2 WAY CROSSOVER BIOEQUIVALENCE STUDY COMPARING NICERGOLINE 10 MG TABLET (MANUFACTURED AT PFIZER DALIAN, CHINA) WITH NICERGOLINE 10 MG TABLET (MANUFACTURED AT PFIZER ITALIA S.R.L., ITALY) UNDER FASTED AND FED CONDITIONS IN HEALTHY CHINESE PARTICIPANTS

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This trial is a bioequivalence study to support a generic consistency evaluation program, initiated by the China Food and Drug Administration (CFDA) in 2015, for the evaluation of quality and efficacy of the products manufactured in China. Related guidance was issued by Center for Drug Evaluation (CDE) on 27 Nov 2015 named "Use pharmacokinetic (PK) parameter as endpoint for chemical generics bioequivalence (BE) study". Nicergoline localized product is manufactured at Pfizer Dalian China, while the reference product is manufactured at Pfizer Italia S.r.l., Italy. The selected strength of 10 mg tablet is the marketed strength in China, and the selected dose of 30 mg (3 x 10 mg tablet) is one of the commonly used clinically approved daily doses with good tolerability profile. In each group, participants will be randomized to one of the 2 treatment sequences according to a computer generated randomization schedule. Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between the first day of each period.

Conditions

Interventions

TypeNameDescription
DRUGNicergoline from ChinaThis is the test arm of China local manufactured Nicergoline
DRUGNicergoline from ItalyThis is the reference arm of Italy originator Nicergoline.

Timeline

Start date
2019-12-17
Primary completion
2020-09-29
Completion
2020-09-29
First posted
2019-11-25
Last updated
2021-01-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04176367. Inclusion in this directory is not an endorsement.